Some new Yescarta data | GILD Message Board Posts

Gilead Sciences, Inc.

  GILD website

GILD   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  11885 of 12025  at  6/11/2019 10:16:57 AM  by


 In response to msg 11884 by  captsolo
view thread

Re: Some new Yescarta data

No offense, but you are wrong.
Yes, liso-cel is a year away from approval, but it's going to happen.   It has a better safety profile allowing for outpatient treatment.  Instead of hospitalizing patients for two weeks, they can stay nearby and come in if there is any problem.  
"would not let them sell it commercially"; It's more a situation where if they can't produce a full dose (typically because of poor quality of cells from very sick patients), they can't charge for it and might as well give whatever they did create to patient.  Kite has 97% on-spec production last we heard.  I believe the 3% of non-conforming product are considered part of the Zuma-9 trial.
JCAR015 is a different construct than JCAR017 (liso-cel).  Different co-stimulatory domains.  Fixed dosage.  They were giving too high a dosage in JCAR015 creating neurotoxicity.
Not trying to be antagonistic.   Just realistic.  

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 254
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
11886 Re: Some new Yescarta data captsolo 0 6/12/2019 8:45:47 AM

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by